Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of DKN-01 in combination with KEYTRUDA (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Trial Profile

A clinical study of DKN-01 in combination with KEYTRUDA (pembrolizumab) patients with relapsed or refractory advanced esophagogastric adenocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs DKN 01 (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2018 According to a Leap Therapeutics media release, results from the study will be presented SITC 2018 Annual Meeting.
    • 21 Oct 2018 According to a Leap Therapeutics media release, Data from the monotherapy and paclitaxel arms of the study have been presented previously and will be updated later in the year. As of the September 26, 2018 cut-off date for the presentation, forty-five patients have been enrolled in the DKN-01 plus pembrolizumab study. The company expects that the PD-1/PD-L1 naive group will complete enrollment before the end of 2018.
    • 21 Oct 2018 According to a Leap Therapeutics media release, results from the study were presented at the European Society for Molecular Oncology (ESMO) 2018 Annual Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top